Hepatic stem cells: A viable approach for the treatment of XXXX .

@entity1 @entity82 @entity39 @entity409 @entity3851 @entity1575
@entity1575 is characterized by distortion of @entity409 , @entity39 of hepatocytes and regenerative nodules formation leading to @entity82 . Various types of cell sources have been used for the management and treatment of decompensated @entity1575 . Knowledge of stem cells has offered a new dimension for regenerative therapy and has been considered as one of the potential adjuvant treatment modality in @entity1 with @entity3851 ( @entity3851 ). @entity1 fetal hepatic progenitor cells are less immunogenic than adult ones. They are highly propagative and challenging to cryopreservation. In our earlier studies we have demonstrated that fetuses at 10-18 wk of gestation age contain a large number of actively dividing hepatic stem and progenitor cells which possess bi-potent nature having potential to differentiate into bile duct cells and mature hepatocytes. Hepatic stem cell therapy for the treatment of @entity3851 is in their early stage of the translation. The emerging technology of decellularization and recellularization might offer a significant platform for developing bioengineered personalized livers to come over the scarcity of desired number of donor organs for the treatment of @entity3851 . Despite these significant advancements long-term tracking of stem cells in @entity1 is the most important subject nowadays in order to answer several unsettles issues regarding the route of delivery, the choice of stem cell type(s), the cell number and the time-point of cell delivery for the treatment in a chronic setting. Answering to these questions will further contribute to the development of safer, noninvasive, and repeatable imaging modalities that could discover better cell therapeutic approaches from bench to bed-side. Combinatorial approach of decellularization and nanotechnology could pave a way towards the better understanding in determination of cell fate post-transplantation.
